Hosted on MSN

Majority of Medicaid managed care plans cover opioid overdose reversal drug naloxone, but access barriers remain

Figure illustrates the proportion of Medicaid managed care plans (MCP) in state covering at least one generic injectable or generic or brand intranasal naloxone formulation without any restrictions.
Yahoo

House: Medicaid managed care plans will be paid $143 billion over the next six years

The state could pay Medicaid managed care plans $143 billion during the next six years to provide care to the state’s poor, elderly, and disabled, a leading House Republican said Tuesday. Rep. Josie ...
The American Journal of Managed Care

State Sanctions May Not Affect Medicaid Managed Care

Sanctions are a key tool that states use to hold Medicaid managed care organizations (MCOs) accountable for their use of public funds. The 2023 reports that MCOs submit ...
Health Affairs

How To Keep Competition Alive In Medicaid Managed Care Markets

This article is part of a Health Affairs Forefront featured topic, Medicaid Financing. The featured topic includes analysis, proposals, and commentary that will inform policies on the state and ...
Becker's Hospital Review

New Hampshire Moves Toward Medicaid Managed Care Plans

The New Hampshire Department of Health and Human Services has announced the state’s Medicaid Care Management program is open for enrollment, a step forward in the state’s plans to transition Medicaid ...
The American Journal of Managed Care

Contributor: Beyond a One-Size-Fits-All for Managed Care Plan Benchmarks

Comparing plans with similar characteristics, such as size, geographic location, or demographics served, allows for more meaningful insights and improvement opportunities. Every year, managed care ...
Medical Xpress

Majority of Medicaid managed care plans cover opioid overdose reversal drug naloxone, but access barriers remain

Figure illustrates the proportion of Medicaid managed care plans (MCP) in state covering at least one generic injectable or generic or brand intranasal naloxone formulation without any restrictions.